Please try another search
            
        
    Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. Its product candidate includes verekitug, which is in Phase 2 clinical development for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps, as well as in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporated in 2021 and is headquartered in Waltham, Massachusetts.
| Name | Age | Since | Title | 
|---|---|---|---|
| Ronald C. Renaud | 55 | 2021 | Independent Chairman of the Board | 
| Daniella Beckman | 45 | - | Independent Director | 
| Erez Chimovits | 60 | 2021 | Independent Director | 
| Marcella K. Ruddy | 61 | 2023 | Independent Director | 
| H. Edward Fleming | 61 | 2023 | Independent Director | 
| Liam Ratcliffe | 61 | 2021 | Independent Director | 
| E. Rand Sutherland | 55 | 2024 | CEO & Director | 
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review